Hairloss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.
Male androgenetic alopecia is commonly treated with topical minoxidil and oral finasteride, both requiring continuous use. Other options include hair restoration surgery, dutasteride, light therapy, and camouflaging agents.
Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hairloss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.
The conversation discusses hairloss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
PP405 is a new hairloss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.